US Representative

Steven Horsford Authored & Sponsored Legislation

Session

Co-Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2368

Introduced
3/26/25  
Raise the Age Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2410

Introduced
3/27/25  
Revitalizing Downtowns and Main Streets Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB247

Introduced
1/9/25  
Health Care Affordability Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2509

Introduced
3/31/25  
COMPLETE Care Act Connecting Our Medical Providers with Links to Expand Tailored and Effective Care
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2540

Introduced
4/1/25  
SSI Savings Penalty Elimination Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2550

Introduced
4/1/25  
Protect America's Workforce Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2585

Introduced
4/1/25  
Armenian Genocide Education Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2586

Introduced
4/1/25  
Reentry Act of 2025

Primary Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2553

Introduced
4/1/25  
Capping Prescription Costs Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2554

Introduced
4/1/25  
Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).